ClinVar Miner

Submissions for variant NM_000051.4(ATM):c.6322C>T (p.Gln2108Ter)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 4
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Color Diagnostics, LLC DBA Color Health RCV003585885 SCV004361792 pathogenic Hereditary cancer-predisposing syndrome 2022-07-11 criteria provided, single submitter clinical testing This variant changes 1 nucleotide in exon 43 of the ATM gene, creating a premature translation stop signal. This variant is expected to result in an absent or non-functional protein product. To our knowledge, this variant has not been reported in individuals affected with hereditary cancer in the literature. This variant has not been identified in the general population by the Genome Aggregation Database (gnomAD). Loss of ATM function is a known mechanism of disease (clinicalgenome.org). Based on the available evidence, this variant is classified as Pathogenic.
Labcorp Genetics (formerly Invitae), Labcorp RCV003605880 SCV004428313 pathogenic Ataxia-telangiectasia syndrome 2024-07-06 criteria provided, single submitter clinical testing This sequence change creates a premature translational stop signal (p.Gln2108*) in the ATM gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in ATM are known to be pathogenic (PMID: 23807571, 25614872). This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with ATM-related conditions. For these reasons, this variant has been classified as Pathogenic.
Myriad Genetics, Inc. RCV004371484 SCV004932360 pathogenic Familial cancer of breast 2024-01-29 criteria provided, single submitter clinical testing This variant is considered pathogenic. This variant creates a termination codon and is predicted to result in premature protein truncation.
Ambry Genetics RCV003585885 SCV005018950 pathogenic Hereditary cancer-predisposing syndrome 2024-01-15 criteria provided, single submitter clinical testing The p.Q2108* pathogenic mutation (also known as c.6322C>T), located in coding exon 42 of the ATM gene, results from a C to T substitution at nucleotide position 6322. This changes the amino acid from a glutamine to a stop codon within coding exon 42. This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). This alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.